Partnering with the Cosmetic Ingredient Review program to formalize cosmetic-ingredient safety assessments would be "inappropriate," potentially raising "significant appearance concerns and resource issues," according to FDA's fiscal 2017 budget justification.
In reports supporting FY 2016 spending bills, Senate and House appropriations committees proposed transferring CIR to the US Pharmacopeial Convention or another "some other appropriate third body," which could provide a
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?